Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/140650

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice
Asó, Ester; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Maldonado, Rafael, 1961-; Ferrer, Isidro (Ferrer Abizanda)
Several recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Moreover, THC + CBD reduced learning impairment in AβPP/PS1 mice. A significant decrease in soluble Aβ42 peptide levels and a change in plaques composition were also observed in THC + CBD-treated AβPP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic form of the Aβ peptide. Among the mechanisms related with these positive cognitive effects, the anti-inflammatory properties of cannabinoids may also play a relevant role. Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AβPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD. Moreover, other cannabinoid-induced effects were uncovered by a genome-wide gene expression study. Thus, we have identified the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects in our AD model. In summary, the present findings show that the combination of THC and CBD exhibits a better therapeutic profile than each cannabis component alone and support the consideration of a cannabis-based medicine as potential therapy against AD.
-Malaltia d'Alzheimer
-Pèptids
-Cervell
-Efectes secundaris dels medicaments
-Marihuana
-Farmacologia
-Plaquetes sanguínies
-Metabolisme
-Alzheimer's disease
-Peptides
-Brain
-Drug side effects
-Marijuana
-Pharmacology
-Blood platelets
-Metabolism
(c) Aso, Ester et al., 2015
Artículo
Artículo - Versión aceptada
IOS Press
         

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Asó, Ester; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Maldonado, Rafael, 1961-; Ferrer, Isidro (Ferrer Abizanda)
Asó, Ester; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Maldonado, Rafael, 1961-; Ferrer, Isidro (Ferrer Abizanda)
Armand-Ugón, Mercedes; Asó, Ester; Moreno Castro, Jesús; Riera i Codina, Miquel; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Ferrer, Isidro (Ferrer Abizanda)
Armand-Ugón, Mercedes; Asó, Ester; Moreno Castro, Jesús; Riera i Codina, Miquel; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Ferrer, Isidro (Ferrer Abizanda)